Heat-Activated Precision Oncology
A precision oncology platform bringing a commercially proven hyperthermia device and clinical-stage heat-activated therapeutics under one roof, so that cancer therapies are activated, enhanced, and directed to the tumor.
A new standard for how cancer is treated.
Avenor Therapeutics is a US-based precision oncology company headquartered in Cambridge, MA, with research rooted in Munich, Germany and Rome, Italy.
To establish Avenor as the global leader in heat-activated precision oncology, making targeted, tumor-focused therapy the cornerstone of modern cancer treatment and beyond, worldwide.
To be the only company combining ownership of a best-in-class, clinically validated and commercially deployed radiative hyperthermia platform with next-generation thermosensitive liposome therapeutics engineered for heat-triggered, tumor-localized release. By uniting drug and device under one roof, we unlock superior combination therapies unachievable by either technology alone, building a scalable, defensible platform for heat-activated precision medicine in the US and globally.
More Than a Drug. More Than a Device.
Precision Hyperthermia
Clinically validated, commercially deployed technology delivering controlled deep-tissue heating with radiotherapy-like precision.
Biological Enhancement
Heat improves tumor oxygenation, inhibits DNA repair mechanisms, and amplifies sensitivity to existing therapies.
Heat-Activated Therapeutics
Next-generation therapeutics engineered to release their payload only when activated within the tumor.
Generating a new treatment pillar in oncology, and beyond.
Get in touch ›